Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 33 EP applications Andrew David Shore has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after October 09, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12718651

DIHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/4709, C07D 401/10, A61P 35/00
Applicant:
GlaxoSmithKline LLC
Applicant:
GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline Intellectual Property Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12716378

TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/4709, A61K 31/4706, C07D 401/12, C07D 215/44, C07D 215/42, A61P 35/00, A61P 29/00
Applicant:
GlaxoSmithKline LLC
Applicant:
GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline Intellectual Property Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12718620

TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/4709, A61K 31/4706, C07D 401/14, C07D 401/12, C07D 401/04, C07D 215/44, A61P 35/00, A61P 29/00
Applicant:
GlaxoSmithKline LLC
Applicant:
GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline
Agent:
Andrew David Shore, GlaxoSmithKline Intellectual Property Limited
Status:
PATENT GRANTED
EP13192666

Benzodiazepine bromodomain inhibitor

IPC classification:
A61K 31/55, C07D 487/04, A61P 43/00, A61P 35/00
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12748028

4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR

IPC classification:
A61K 31/4745, C07D 471/04, A61P 37/00, A61P 29/00
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
PATENT GRANTED
EP12761738

MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

IPC classification:
A61K 31/53, C07D 413/04, C07D 407/12, C07D 401/12, C07D 251/22, A61P 37/08, A61P 37/06, A61P 37/04, A61P 37/02, A61P 35/00
Applicant:
Cellzome Ltd
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
PATENT GRANTED
EP12769098

MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

IPC classification:
A61K 31/519, C07D 417/02
Applicant:
Cellzome Ltd
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13703017

PI3K INHIBITORS FOR TREATING COUGH

IPC classification:
A61K 31/5377, A61K 31/501, A61P 11/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12826498

BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS

IPC classification:
A61K 31/69, A61P 31/14
Applicant:
Glaxo Group Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
PATENT GRANTED
EP13737782

NICOTINAMIDE DERIVATE IN THE TREATMENT OF ACUTE CORONARY SYNDROME

IPC classification:
A61K 31/455, A61K 9/00, A61P 9/10
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP13750830

BENZODIAZEPINES FOR TREATING SMALL CELL LUNG CANCER

IPC classification:
A61K 31/5517, A61P 35/00
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
The patent has been granted
EP14735983

LOSMAPIMOD FOR USE IN TREATING GLOMERULAR DISEASE

IPC classification:
A61P 13/12, A61K 45/06, A61K 31/455
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16150637

NOVEL BENZODIAZEPINE COMPOUND

IPC classification:
A61K 31/5517, A61P 43/00, A61P 35/00, A61K 31/55, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
The patent has been granted
EP16152464

BENZODIAZEPINE BROMODOMAIN INHIBITOR

IPC classification:
A61P 43/00, A61P 35/00, A61K 31/55, C07D 487/04
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
The patent has been granted
EP15710919

METHODS OF TREATING CANCER PATIENTS RESPONDING TO EZH2 INHIBITOR GSK126

IPC classification:
A61K 31/00, G01N 33/574
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15715424

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61P 35/00, A61K 45/06, C07D 471/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16192662

4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR

IPC classification:
A61P 37/00, A61P 29/00, A61K 31/4745, C07D 471/04
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16197070

TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS

IPC classification:
A61P 35/00, A61P 29/00, A61K 31/4709, A61K 31/4706, C07D 401/12, C07D 401/14, C07D 401/04, C07D 215/44
Applicant:
GlaxoSmithKline LLC
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
The patent has been granted
EP15760461

TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS

IPC classification:
A61P 35/00, A61P 29/00, A61P 31/12, A61K 31/4709, C07D 401/12, C07D 405/14
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16195408

BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS

IPC classification:
A61P 31/14, A61K 31/34, A61K 31/69, A61K 31/343, C07F 5/04, C07D 307/85
Applicant:
Glaxo Group Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16191843

PROCESSES FOR MAKING LACTOSE UTILIZING PRE-CLASSIFICATION TECHNIQUES AND PHARMACEUTICAL FORMULATIONS FORMED THEREFROM

IPC classification:
A61K 9/00, C13K 5/00, C07H 3/00, A61K 31/715, A61K 31/7016
Applicant:
DMV-Fonterra Excipients Technology GmbH
Applicant:
Glaxo Group Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP15771952

COMPOUND

IPC classification:
A61P 43/00, A61P 35/00, A61K 31/5517, C07D 487/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP15786958

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4427, A61K 31/381, C07D 495/04, C07D 409/14, C07D 413/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP15816887

NOVEL METHOD OF USE

IPC classification:
A61K 31/05, A61K 45/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16725243

TOPICAL PHARMACEUTICAL COMPOSITIONS

IPC classification:
A61K 9/113, A61K 9/107, A61K 9/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16735714

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4545, A61K 31/55, C07D 495/04, C07D 409/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16766865

PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/501, C07D 401/12
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16770800

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

IPC classification:
A61P 3/00, A61P 25/00, A61P 35/00, C07D 495/04, A61K 31/519, C07D 487/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16774992

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

IPC classification:
A61K 31/433, A61K 31/41, C07D 285/08, C07D 277/80, C07D 263/58, C07D 263/48, C07D 417/12, C07D 413/12, C07D 235/30, C07D 403/12
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16771000

COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY

IPC classification:
A61P 31/18, A61K 31/56, C07D 211/96, C07J 63/00, C07D 279/12
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16774993

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

IPC classification:
A61P 31/18, A61K 31/426, A61K 31/421, A61K 31/433, A61K 31/44, C07D 307/66, C07D 285/00, C07D 277/82, C07D 263/58, C07D 263/48, C07D 253/06, C07D 241/20, C07D 239/42, C07D 235/30, C07D 333/20, C07D 309/14, C07D 213/74
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16766979

PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS

IPC classification:
A61K 31/501, C07D 401/12
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made
EP16778310

2-OXO-1,2-DIHYDROPYRIDINE-3,5-DICARBOXAMIDE COMPOUNDS AS BROMODOMAIN INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4439, A61K 31/4412, C07D 401/12, C07D 213/82, C07D 401/14
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Andrew David Shore, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature